Prophylactic cranial irradiation in patients with small-cell lung cancer: the experience at the Institute of Oncology Ljubljana.
Prophylactic cranial irradiation in patients with small-cell lung cancer: the experience at the Institute of Oncology Ljubljana.
复制标题
DOI：
10.2478/v10019-010-0038-4
复制
发表时间：
2010-09
影响因子：
2.4
通讯作者：
Kovac V
中科院分区：
文献类型：
--
作者：
Stanic K;Kovac V
小细胞肺癌(SCLC)患者已采用预防性颅脑照射(PCI)，以减少脑转移(BM)的发生率，从而提高总生存率。这项回顾性研究的目的是分析卢布尔雅那肿瘤研究所转诊的小细胞肺癌患者的特征、他们接受经皮冠状动脉介入治疗的资格、扩散模式和存活率。回顾2004年1月至2006年12月卢布尔雅那肿瘤研究所收治的357例小细胞肺癌患者的病历，以确定选择行经皮冠状动脉介入治疗的患者的特征。收集了以下数据：年龄、性别、功能状态(PS)、疾病程度、吸烟状况、主要治疗类型和结果、血液学和生化参数、冠状动脉介入治疗的使用，最后是诊断和治疗后的脑转移(BM)状态。24例(6.7%)行了经皮冠状动脉介入治疗。6例(25%)患者在接受经皮冠状动脉介入治疗后发生脑转移。4例仅脑转移，2例进展为多器官转移。接受经皮冠状动脉介入治疗的患者的中位总生存期为21.9月，未行经皮冠状动脉介入治疗的患者的中位生存期为12.13月(p=0.004)。从收集的数据中，有良好的预后因素：年龄在65岁以下，有局限性疾病(LD)，运动状态，乳酸脱氢酶(LDH)正常水平和C反应蛋白(CRP)水平正常。其他预后因素无统计学意义。接受过经皮冠状动脉介入治疗的LD患者的存活率明显好于没有接受过冠状动脉介入治疗的患者。我们决定对LD患者、完全或接近完全缓解的患者以及状态良好的患者(≥80)进行经皮冠状动脉介入治疗。我们没有在扩张性疾病(ED)中使用经皮冠状动脉介入治疗。这其中的原因将在未来得到解决。经皮冠状动脉介入治疗的剂量并不一致，因此应该考虑更标准的方法。
Prophylactic cranial irradiation (PCI) has been used in patients with small-cell lung cancer (SCLC) to reduce the incidence of brain metastases (BM) and thus increase overall survival. The aim of this retrospective study was to analyze the characteristics of patients with SCLC referred to the Institute of Oncology Ljubljana, their eligibility for PCI, patterns of dissemination, and survival. Medical charts of 357 patients with SCLC, referred to the Institute of Oncology Ljubljana between January 2004 and December 2006, were reviewed to determine characteristics of patients chosen for PCI. The following data were collected: age, gender, performance status (PS), extent of the disease, smoking status, type of primary treatment with outcome, haematological and biochemical parameters, PCI use, and finally brain metastases (BM) status at diagnoses and after treatment. PCI was performed in 24 (6.7%) of all patients. Six (25%) patients developed brain metastases after they were treated with PCI. Brain was the only site of metastases in 4 patients, two progressed to multiple organs. Median overall survival of patients with PCI was 21.9 months, without PCI 12.13 months (p = 0.004). From the collected data there were good prognostic factors: age under 65 years, limited disease (LD), performance status, normal levels of lactate dehydrogenase (LDH) and normal levels of C-reactive protein levels (CRP). Other prognostic factors did not show statistical significant values. Survival of patients with LD, who have had PCI, was significantly better than those who had not. We decided to perform PCI in patients with LD, in those with complete or near complete response, and those with good performance status (≥ 80). We did not use PCI in extended disease (ED). The reason for that shall be addressed in the future. Doses for PCI were not uniform, therefore more standard approach should be considered.
登录
查看更多内容
影响因子：
2.4
作者：
Debevec, Lucka;Jeric, Tina;Sok, Miha
通讯作者：
Sok, Miha
影响因子：
2.4
作者：
Bisof, Vesna;Juretic, Antonio;Stern, Ranka Padovan
通讯作者：
Stern, Ranka Padovan
影响因子：
3.8
作者：
Meert AP;Paesmans M;Berghmans T;Martin B;Mascaux C;Vallot F;Verdebout JM;Lafitte JJ;Sculier JP
通讯作者：
Sculier JP
影响因子：
6.2
作者：
Grosshans, David R.;Meyers, Christina A.;Komaki, Ritsuko
通讯作者：
Komaki, Ritsuko
影响因子：
158.5
作者：
Aupérin, A;Arriagada, R;Aisner, J
通讯作者：
Aisner, J